RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Santen Pharmaceutical Co Stock

Santen Pharmaceutical Co EBIT 2024

Santen Pharmaceutical Co EBIT

52.69 B JPY

Ticker

4536.T

ISIN

JP3336000009

WKN

864318

In 2024, Santen Pharmaceutical Co's EBIT was 52.69 B JPY, a 49.26% increase from the 35.3 B JPY EBIT recorded in the previous year.

The Santen Pharmaceutical Co EBIT history

YEAREBIT (undefined JPY)
2027e47.52
2026e52.2
2025e51.3
202452.69
202335.3
202235.98
202137.56
202039.86
201941.39
201838.8
201732.48
201680.18
201535.37
201427.31
201324.68
201226.73
201130.74
201029.64
200915.49
200820.34
200720.06
200620.67
200518.66

Santen Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Santen Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Santen Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Santen Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Santen Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Santen Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Santen Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Santen Pharmaceutical Co’s growth potential.

Santen Pharmaceutical Co Revenue, EBIT and net profit per share

DateSanten Pharmaceutical Co RevenueSanten Pharmaceutical Co EBITSanten Pharmaceutical Co Net Income
2027e301.2 B undefined47.52 B undefined41.81 B undefined
2026e297.77 B undefined52.2 B undefined39.34 B undefined
2025e299.14 B undefined51.3 B undefined35.69 B undefined
2024301.97 B undefined52.69 B undefined26.63 B undefined
2023279.04 B undefined35.3 B undefined-14.96 B undefined
2022266.26 B undefined35.98 B undefined27.21 B undefined
2021249.61 B undefined37.56 B undefined9.31 B undefined
2020241.56 B undefined39.86 B undefined23.62 B undefined
2019234.03 B undefined41.39 B undefined31.95 B undefined
2018224.94 B undefined38.8 B undefined35.25 B undefined
2017199.1 B undefined32.48 B undefined21.73 B undefined
2016195.29 B undefined80.18 B undefined53.37 B undefined
2015161.83 B undefined35.37 B undefined24.03 B undefined
2014148.66 B undefined27.31 B undefined17.11 B undefined
2013119.07 B undefined24.68 B undefined16.52 B undefined
2012114.42 B undefined26.73 B undefined17.16 B undefined
2011110.81 B undefined30.74 B undefined21.33 B undefined
2010110.59 B undefined29.64 B undefined18.72 B undefined
2009101.62 B undefined15.49 B undefined10.12 B undefined
2008103.39 B undefined20.34 B undefined12.65 B undefined
2007100.49 B undefined20.06 B undefined13.15 B undefined
200698.4 B undefined20.67 B undefined13.02 B undefined
200592.7 B undefined18.66 B undefined11 B undefined

Santen Pharmaceutical Co stock margins

The Santen Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Santen Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Santen Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Santen Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Santen Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Santen Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Santen Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Santen Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Santen Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Santen Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Santen Pharmaceutical Co Margin History

Santen Pharmaceutical Co Gross marginSanten Pharmaceutical Co Profit marginSanten Pharmaceutical Co EBIT marginSanten Pharmaceutical Co Profit margin
2027e59.18 %15.78 %13.88 %
2026e59.18 %17.53 %13.21 %
2025e59.18 %17.15 %11.93 %
202459.18 %17.45 %8.82 %
202359.52 %12.65 %-5.36 %
202258.81 %13.51 %10.22 %
202160.65 %15.05 %3.73 %
202060.74 %16.5 %9.78 %
201961.22 %17.69 %13.65 %
201861.6 %17.25 %15.67 %
201762.35 %16.31 %10.91 %
201662.71 %41.06 %27.33 %
201565.17 %21.86 %14.85 %
201460.92 %18.37 %11.51 %
201365.14 %20.73 %13.87 %
201269.07 %23.36 %15 %
201168.92 %27.74 %19.25 %
201068.61 %26.8 %16.93 %
200964.63 %15.25 %9.96 %
200864.69 %19.67 %12.23 %
200764.69 %19.96 %13.08 %
200664.9 %21 %13.23 %
200563.63 %20.13 %11.86 %

Santen Pharmaceutical Co Aktienanalyse

What does Santen Pharmaceutical Co do?

Santen Pharmaceutical Co., Ltd. is a Japanese company specializing in the development and marketing of pharmaceutical products and medical devices. With its headquarters in Osaka, Japan, Santen was founded in October 1890 as Fukuhara Helper's Institute Co., Ltd. Santen started as a small contact lens manufacturer and distributor in 1936, focusing on producing and selling high-quality contact lenses. Over time, the company expanded its product offerings to include ophthalmic products such as eye drops and other medications. In the 1990s, Santen further expanded its business by acquiring other companies and establishing its own research and development department to develop innovative products. Today, Santen is part of a global network of companies specializing in the development and marketing of ophthalmic products. Santen operates in various business areas, including ophthalmology, dermatological and anti-rheumatic medications, as well as medical devices and diagnostic instruments. The company has a presence in over 60 countries worldwide, with branches in the USA, Europe, and Asia. In the field of ophthalmology, Santen offers a wide range of products for the treatment of eye diseases such as glaucoma, dry eye, and allergic conditions. The company has also developed advanced devices for ophthalmology, such as lasers for the treatment of various eye diseases. Santen has also invested in dermatological medicine by offering medications for various skin conditions, including acne, psoriasis, and eczema. Additionally, the company provides medical devices for the diagnosis and monitoring of skin conditions. Specializing in the development of anti-rheumatic medications, Santen offers therapies for conditions such as rheumatoid arthritis and psoriatic arthritis. The company has collaborated with other companies to develop innovations in this field. Santen's business model revolves around developing and marketing innovative products for the healthcare industry. The company aims to provide patients worldwide with access to the best treatments and medical devices. Santen prioritizes research and development, investing a significant portion of its revenue in the development of new products. Overall, Santen offers a wide range of products and services that are in high demand in the healthcare sector. The company has established itself as an innovative provider of top-quality solutions in ophthalmology, dermatology, and rheumatology worldwide. With its strong presence in various countries, Santen continues to invest in the research and introduction of new products that can improve the health and well-being of people. Santen Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Santen Pharmaceutical Co's EBIT

Santen Pharmaceutical Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Santen Pharmaceutical Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Santen Pharmaceutical Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Santen Pharmaceutical Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Santen Pharmaceutical Co stock

How much did Santen Pharmaceutical Co achieve in EBIT for the current year?

In the current year, Santen Pharmaceutical Co has achieved an EBIT of 52.69 B JPY.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Santen Pharmaceutical Co.

How has the EBIT of Santen Pharmaceutical Co developed in recent years?

The EBIT of Santen Pharmaceutical Co has increased by 49.263% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Santen Pharmaceutical Co?

The EBIT of Santen Pharmaceutical Co is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Santen Pharmaceutical Co pay?

Over the past 12 months, Santen Pharmaceutical Co paid a dividend of 34 JPY . This corresponds to a dividend yield of about 1.88 %. For the coming 12 months, Santen Pharmaceutical Co is expected to pay a dividend of 34.87 JPY.

What is the dividend yield of Santen Pharmaceutical Co?

The current dividend yield of Santen Pharmaceutical Co is 1.88 %.

When does Santen Pharmaceutical Co pay dividends?

Santen Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Santen Pharmaceutical Co?

Santen Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Santen Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 34.87 JPY are expected. This corresponds to a dividend yield of 1.93 %.

In which sector is Santen Pharmaceutical Co located?

Santen Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Santen Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Santen Pharmaceutical Co from 12/1/2024 amounting to 17 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Santen Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Santen Pharmaceutical Co in the year 2023?

In the year 2023, Santen Pharmaceutical Co distributed 32 JPY as dividends.

In which currency does Santen Pharmaceutical Co pay out the dividend?

The dividends of Santen Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Santen Pharmaceutical Co

Our stock analysis for Santen Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Santen Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.